Skip to content

Vaginal Estradiol Use in Pessary Care

Vaginal Estradiol Use in Pessary Management: A Randomized Controlled Trial

Status
Terminated
Phases
Early Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05458375
Enrollment
11
Registered
2022-07-14
Start date
2022-12-29
Completion date
2023-04-26
Last updated
2023-05-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pelvic Organ Prolapse, Pessary Ulcer of Vagina, Urinary Incontinence, Vaginal Atrophy

Keywords

pessary, vaginal estradiol

Brief summary

The primary outcome of this study compare the rate of pessary discontinuation at 6 months post-pessary fitting in women using vaginal estradiol versus those not using vaginal estradiol.

Detailed description

The purpose of the study is to investigate the effects of vaginal estradiol cream on pessary care. All patients presenting to the University of South Florida Urogynecology clinic for pessary fitting for pelvic organ prolapse and/or urinary incontinence are screened as potential study participants. After being informed of risks and benefits of participations and consent is obtained, patients that have been successfully fitted for a pessary and agree to participate will be separated into two groups: the control group or treatment group. The treatment group will be provided with a prescription for vaginal estradiol cream. Vaginal estradiol cream is FDA approved and is the first line treatment for vaginal atrophy, also known as dryness. The study will be unblinded and randomized, neither the participant nor the study doctor will choose which group the will be participant will be placed in. The participant will have an equal chance of being given either treatment. The treatment group will be asked to apply vaginal estradiol cream nightly for two weeks and then twice weekly thereafter. All participants will have 2 study visits over a 6-month period which is standard for pessary care: a regular follow up pessary check visit two weeks after pessary fitting and second visit 6 months later. At these visits, questions regarding symptoms including vaginal bleeding, vaginal discharge, and discomfort with pessary will be assessed and a physical exam will be performed as is standard for all pessary users.

Interventions

Insert pea-sized amount of vaginal estradiol cream into vagina nightly for first two weeks and then twice weekly thereafter.

Sponsors

University of South Florida
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Intervention model description

The study design will be a randomized controlled trial involving patients seen in the Urogynecology clinic with pelvic organ prolapse or incontinence who were recently fit with a pessary.

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Age ≥ 18 years * Postmenopausal status * Recent pessary fitting * Office-based and home-based pessary care

Exclusion criteria

* Women \< 18 years old * Women currently on hormone replacement therapy (pill, patch, pellet) * Women currently using vaginal estradiol cream within the last 4 weeks * Medical contraindications to vaginal estradiol including unevaluated vaginal bleeding * Inability to apply vaginal estradiol cream * Inability to provide informed consent * Inability to comprehend written and/or spoken English or Spanish * Inability to comply with study visit schedule

Design outcomes

Primary

MeasureTime frameDescription
Pessary Discontinuation Rates6 Months Post-Pessary FittingTo compare the rate of pessary discontinuation at 6 months post-pessary fitting in estrogen group and no intervention group

Secondary

MeasureTime frameDescription
Unscheduled office visits6 Months Post-Pessary FittingTo compare the number of unscheduled office visits from patients in estrogen group and no intervention group
Vaginal BleedingBaseline Visit (Pessary Fitting), Final Visit (6 Months Post-Pessary Fitting)To compare the rates of vaginal bleeding from patients in estrogen group and no intervention group. As is standard in our practice, the pessary check visit includes an interview with the patient where specific self-reported symptoms are assessed. Participants will answer with self-reported yes/no during interview at the baseline study visit and at the final study visit.
Pessary DiscomfortBaseline Visit (Pessary Fitting), Final Visit (6 Months Post-Pessary Fitting)To compare the degrees of pessary discomfort using visual analogue scale measured in millimeters between patients in estrogen group and no intervention group. On this scale, the value 1 reflects no complaints of this side-effect and 10 reflects very severe complaints of this side-effect.
Phone calls/messages6 Months Post-Pessary FittingTo compare the number of phone calls/messages from patients to the office regarding pessary management symptoms in estrogen group and no intervention group
Urinary Tract Infection RatesFinal Visit (6 Months Post-Pessary Fitting)To compare the rates of urinary tract infections between patients in estrogen group and no intervention group. The diagnosis of urinary tract infection (UTI) is based on confirmatory testing, specifically with urine culture.
Vaginal Erosion RatesFinal Visit (6 Months Post-Pessary Fitting)To compare the rates of vaginal erosions between patients in estrogen group and no intervention group. Any vaginal erosions will be noted during the vaginal exam at the final visit, which is standard in our practice. Vaginal erosions are described using the following definitions: Type 0: No abnormalities; Type 1: Epithelial erythema; Type 2: Granulation tissue; Type 3: Epithelial break or erosion ≤ 1 cm; Type 4: Epithelial break or erosion \> 1 cm.
Vaginal DischargeBaseline Visit (Pessary Fitting), Final Visit (6 Months Post-Pessary Fitting)To compare the degrees of bother of vaginal discharge using visual analogue scale measured in millimeters between patients in estrogen group and no intervention group. On this scale, the value 1 reflects no complaints of this side-effect and 10 reflects very severe complaints of this side-effect.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026